In a groundbreaking move within the biotechnology sector, Voyager Therapeutics recently announced a strategic licensing deal with Novartis, catapulting its shares up by an impressive 35% in premarket trading. The collaboration involves Novartis making an upfront payment of $100 million to gain exclusive access to Voyager's cutting-edge RNA-based screening...
Voyager Therapeutics (VYGR) has signed an agreement through which Pfizer Inc. (PFE) may exercise options to license novel capsids generated from Voyager's TRACER screening technology to treat certain neurologic and cardiovascular diseases.
Under terms of the deal, Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac...
Voyager Therapeutics Inc (NASDAQ:VYGR) broke above resistance in Friday's trading session after a small period of consolidation. I still like this stock and will be watching it again on Monday, expecting to see a continuation move.
See my detailed trade on the chart. Enjoy!
Green = Profit target
Red = Stoploss
My position size is based on my risk tolerance given the stoploss level.
If you like my content, feel free to support my Pro membership by sending a "Cheer".
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June...
BREAKOUT STOCK ALERT UPDATE
$VYGR - Voyager Therapeutics, Inc. - Common Stock
Initial Alert Price: $8.38
Price High: $7.19
% Gains/Losses: -14.2%
(-29.63% Less Than Expected)
Potential Stop Loss: $6.8305
VYGR is currently trading below our 10% Sell Threshold but we have are watching to determine if the stock breaks below the current support levels around the...
Voyager Therapeutics Inc is functional in the United States biotechnology industry. Its focus lies in the research and development of gene therapies for the cure of severe diseases of the central nervous system such as the Parkinson's, Huntington's and Alzheimer's disease. The company has developed products such as VY-AADC01 for Advanced Parkinson's Disease,...
Voyager therapeutics could jump up on another surprise earnings
The 50 day Moving average is below the 100 and 200 day moving - volume is up
and earnings have amazing earnings up 60% and 1300% these last few quarters so.... it might turn around - I am not buying at this price though.
How long can you out perform with your stock falling ?
I don't know.
The stock has never been cheaper (except covid crash) so it looks like a nice opportunity for a long.
Moreover there is a gap to be filled.
Going long with a tight stop - might be a nice reward without too much risk.
Possible stop below 9.8
Not a recommendation
Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its...
this stock has taken a beating and will rise again
the RSI is very low and earnings are set to come on AUG 10th.
It looks like everyone thinks the report will be bad - I will buy again if it dips to 9.50 , 9 or even 8.
we see a Low RSI and a break out is incoming also 50/100/200 moving averages are tightening before a break out. But investors first have to understand that the deal is over but they will rise again
VYGR has reached a strong support area while the RSI has had higher lows indicating accumulation. The MACD is also increasing and is almost positive.
Expecting the price to increase steadily soon.
Look out for the bull cross of EMA9 of EMA21. This will accelerate the price rise.
The next earnings are on Feb 26.
